{
  "catheter_ablation": {
    "overview": {
      "definition": "Invasive procedure to isolate pulmonary veins and eliminate AF triggers/substrate",
      "success_rates": {
        "paroxysmal_af": "80-90% freedom from AF at 1 year (single procedure)",
        "persistent_af": "60-80% freedom from AF at 1 year (single procedure)",
        "repeat_procedures": "85-95% success after multiple procedures"
      },
      "durability": "Long-term success maintained in 70-80% at 5 years"
    },
    "indications": {
      "class_i": [
        "Symptomatic paroxysmal AF refractory to or intolerant of ≥1 AAD",
        "Symptomatic persistent AF refractory to or intolerant of ≥1 AAD"
      ],
      "class_iia": [
        "First-line therapy for symptomatic paroxysmal AF (patient preference)",
        "AF-mediated cardiomyopathy",
        "Symptomatic AF patients with heart failure"
      ],
      "emerging_indications": [
        "Asymptomatic AF with reduced EF",
        "Young patients to avoid lifelong AADs",
        "Athletes with AF"
      ]
    },
    "patient_selection": {
      "ideal_candidates": [
        "Age <65 years",
        "Paroxysmal AF",
        "Normal LA size (<40mm)",
        "No significant structural heart disease",
        "Symptomatic despite medical therapy"
      ],
      "relative_contraindications": [
        "LA size >55mm",
        "Severe mitral regurgitation",
        "Severe LV dysfunction (EF <30%)",
        "Inability to anticoagulate",
        "Life expectancy <1 year"
      ],
      "absolute_contraindications": [
        "Intracardiac thrombus",
        "Active infection",
        "Pregnancy",
        "Severe bleeding disorder"
      ]
    },
    "pre_procedural_evaluation": {
      "imaging": [
        "Transthoracic echocardiogram (LA size, LV function, valves)",
        "TEE to exclude thrombus (especially if suboptimal anticoagulation)",
        "Cardiac CT or MRI for LA anatomy and PV assessment",
        "Consider coronary angiography if CAD risk factors"
      ],
      "laboratory": [
        "CBC, CMP, PT/PTT/INR",
        "TSH",
        "Type and screen",
        "Pregnancy test (women of childbearing age)"
      ],
      "anticoagulation": [
        "Therapeutic anticoagulation ≥3 weeks pre-procedure",
        "INR 2.0-3.0 (warfarin) or therapeutic DOAC",
        "Continue through procedure (uninterrupted approach preferred)"
      ]
    },
    "procedure_details": {
      "approach": {
        "vascular_access": "Femoral vein cannulation (typically 2-3 sheaths)",
        "transseptal_puncture": "Single or double transseptal puncture",
        "intracardiac_echocardiography": "Real-time imaging guidance"
      },
      "ablation_strategy": {
        "standard": "Pulmonary vein isolation (PVI) - cornerstone of all procedures",
        "additional_lesions": [
          "Linear lesions (roof line, mitral isthmus)",
          "Complex fractionated atrial electrograms (CFAE)",
          "Posterior wall isolation",
          "Left atrial appendage isolation"
        ]
      },
      "energy_sources": {
        "radiofrequency": {
          "advantages": "Precise, well-established, real-time assessment",
          "technique": "Point-by-point ablation with contact force sensing",
          "power": "25-35 watts",
          "temperature": "Target <45°C"
        },
        "cryoablation": {
          "advantages": "Balloon-based, faster procedure, less pain",
          "technique": "Balloon occlusion of PV ostia",
          "freeze_cycle": "-40 to -50°C for 180-240 seconds",
          "limitations": "Less precise, cannot perform linear lesions"
        },
        "pulsed_field_ablation": {
          "advantages": "Tissue-selective, reduces collateral damage",
          "status": "Emerging technology, FDA approved 2023",
          "mechanism": "Irreversible electroporation"
        }
      },
      "procedural_endpoints": [
        "Entrance block: No conduction into PVs",
        "Exit block: No conduction out of PVs",
        "Adenosine testing: No dormant conduction",
        "Non-inducibility of AF (if applicable)"
      ]
    },
    "complications": {
      "major": {
        "incidence": "2-5%",
        "types": [
          {
            "complication": "Stroke/TIA",
            "incidence": "0.5-1%",
            "prevention": "Therapeutic anticoagulation, ICE guidance, air embolism prevention",
            "management": "Immediate neurology consultation, IV thrombolytics if appropriate"
          },
          {
            "complication": "Cardiac tamponade",
            "incidence": "1-2%",
            "recognition": "Hypotension, elevated JVP, pulsus paradoxus",
            "management": "Immediate pericardiocentesis, volume resuscitation"
          },
          {
            "complication": "Pulmonary vein stenosis",
            "incidence": "<1% (with modern techniques)",
            "prevention": "Avoid ablation within PVs, anatomic mapping",
            "symptoms": "Dyspnea, hemoptysis, recurrent pneumonia"
          },
          {
            "complication": "Atrio-esophageal fistula",
            "incidence": "0.1-0.25%",
            "prevention": "Esophageal temperature monitoring, reduced power on posterior wall",
            "presentation": "Fever, sepsis, neurologic symptoms 1-4 weeks post-procedure"
          }
        ]
      },
      "minor": {
        "incidence": "5-10%",
        "types": [
          "Vascular complications (hematoma, pseudoaneurysm)",
          "Transient phrenic nerve palsy",
          "Pericarditis",
          "Radiation skin injury (rare with modern techniques)"
        ]
      }
    },
    "post_procedural_care": {
      "immediate": [
        "4-6 hours bed rest with leg immobilization",
        "Continuous cardiac monitoring",
        "Vital signs and vascular checks q15min x 4, then q30min x 4",
        "Echocardiogram if tamponade suspected",
        "Chest X-ray to rule out pneumothorax"
      ],
      "anticoagulation": [
        "Resume therapeutic anticoagulation 3-4 hours post-procedure",
        "Continue anticoagulation ≥2 months (regardless of CHADSVASC score)",
        "Long-term anticoagulation based on CHADSVASC score"
      ],
      "medications": [
        "Continue pre-procedure AADs for 3 months (blanking period)",
        "PPI for 4-6 weeks (reduce esophageal inflammation)",
        "Colchicine 0.6mg BID x 3 months (reduce pericarditis)"
      ]
    },
    "blanking_period": {
      "definition": "First 3 months post-ablation when AF recurrence doesn't count as failure",
      "rationale": "Inflammation and healing may cause transient arrhythmias",
      "management": [
        "Continue AADs during this period",
        "Cardioversion acceptable for sustained episodes",
        "Don't discontinue anticoagulation solely based on AF absence"
      ]
    },
    "follow_up_protocol": {
      "timeline": [
        {
          "timepoint": "1-2 weeks",
          "assessment": "Wound check, symptoms, basic metabolic panel",
          "actions": "Address any immediate concerns"
        },
        {
          "timepoint": "3 months",
          "assessment": "Symptoms, ECG, 24-48 hour Holter monitor",
          "actions": "Discontinue AAD if no recurrence, reassess anticoagulation"
        },
        {
          "timepoint": "6 months",
          "assessment": "Symptoms, ECG, event monitor or 7-day Holter",
          "actions": "Consider repeat procedure if symptomatic recurrence"
        },
        {
          "timepoint": "12 months",
          "assessment": "Comprehensive evaluation, extended monitoring",
          "actions": "Long-term management plan, anticoagulation decision"
        }
      ],
      "monitoring_strategies": [
        "7-14 day Holter monitors",
        "30-day event monitors",
        "Smartphone-based ECG (AliveCor, Apple Watch)",
        "Implantable loop recorder (selected patients)"
      ]
    },
    "success_definition": {
      "primary_endpoint": "Freedom from AF/AT/AFL >30 seconds after 3-month blanking period",
      "secondary_endpoints": [
        "Reduction in AF burden",
        "Improvement in symptoms/quality of life",
        "Reduction in hospitalizations"
      ],
      "monitoring_requirements": "≥7 days of monitoring at 6-12 months"
    },
    "repeat_procedures": {
      "indications": [
        "Symptomatic AF recurrence >3 months post-ablation",
        "Documentation of AF on extended monitoring"
      ],
      "success_rates": "Additional 15-20% success with repeat procedures",
      "strategy": [
        "Assess PV reconnection (most common mechanism)",
        "Additional substrate modification",
        "Linear lesions or posterior wall isolation"
      ]
    },
    "special_populations": {
      "heart_failure": {
        "benefits": "CASTLE-AF trial showed mortality benefit",
        "considerations": "Higher complication risk, may need staged approach",
        "outcomes": "Significant improvement in EF and symptoms"
      },
      "elderly": {
        "age_considerations": ">75 years associated with lower success, higher complications",
        "selection": "Careful risk-benefit analysis, consider comorbidities",
        "alternative": "Rate control may be preferred in very elderly"
      },
      "persistent_af": {
        "challenges": "Lower success rates, more extensive substrate",
        "strategy": "PVI + additional lesions often required",
        "duration_effect": "Success inversely related to AF duration"
      }
    },
    "alternative_procedures": {
      "surgical_ablation": {
        "indications": "Concomitant cardiac surgery, failed catheter ablation",
        "technique": "Cut-and-sew or cryoablation, LAA exclusion",
        "success_rates": "90-95% for concomitant procedures"
      },
      "hybrid_procedures": {
        "approach": "Combined surgical and catheter ablation",
        "indications": "Persistent AF, failed previous ablations",
        "advantage": "Epicardial and endocardial approach"
      },
      "left_atrial_appendage_occlusion": {
        "indications": "High stroke risk, contraindication to anticoagulation",
        "devices": "Watchman, Amulet",
        "note": "Not a treatment for AF rhythm, only stroke prevention"
      }
    },
    "cost_effectiveness": {
      "upfront_cost": "$15,000-25,000 per procedure",
      "long_term_savings": "Reduced hospitalizations, medication costs, improved QOL",
      "cost_per_qaly": "Favorable in symptomatic patients <65 years"
    },
    "patient_counseling": {
      "realistic_expectations": [
        "70-90% chance of significant improvement",
        "May need 2-3 procedures for optimal results",
        "Complete cure not guaranteed",
        "Some patients may still need medications"
      ],
      "lifestyle_modifications": [
        "Weight loss if overweight (>10% weight loss reduces AF)",
        "Alcohol moderation (<1 drink/day)",
        "Sleep apnea treatment",
        "Regular exercise program",
        "Stress management"
      ],
      "warning_signs": [
        "Chest pain or severe shortness of breath",
        "Signs of stroke (FAST assessment)",
        "Fever >101°F after first few days",
        "Excessive bleeding or large hematoma"
      ]
    }
  },
  "cardioversion": {
    "overview": {
      "definition": "Restoration of normal sinus rhythm using electrical or pharmacologic methods",
      "success_rates": "85-95% electrical, 50-70% pharmacologic"
    },
    "indications": [
      "Hemodynamically unstable AF/AFL",
      "Recent-onset AF in stable patients",
      "Symptomatic AF refractory to rate control",
      "AF-mediated cardiomyopathy"
    ],
    "electrical_cardioversion": {
      "preparation": [
        "Informed consent",
        "NPO ≥4-6 hours",
        "IV access",
        "Continuous monitoring",
        "Emergency equipment available"
      ],
      "anticoagulation_strategy": {
        "duration_less_48h": "Can proceed without anticoagulation if low stroke risk",
        "duration_more_48h": "3-4 weeks therapeutic anticoagulation before, 4 weeks after",
        "unknown_duration": "Treat as >48 hours",
        "tee_guided": "TEE to exclude thrombus → immediate cardioversion → 4 weeks anticoagulation"
      },
      "procedure": {
        "sedation": "Propofol or etomidate preferred",
        "pad_placement": "Anterior-posterior preferred over anterior-lateral",
        "energy": "Biphasic 200J initially, escalate to 300J, then 360J",
        "synchronization": "ALWAYS synchronized to avoid VF induction"
      },
      "post_procedure": [
        "Monitor until fully awake",
        "12-lead ECG to confirm rhythm",
        "Vital signs stable before discharge",
        "Resume anticoagulation if indicated"
      ]
    },
    "pharmacologic_cardioversion": {
      "agents": {
        "amiodarone": {
          "dosing": "15mg/kg IV over 24h, then 0.5-1mg/min maintenance",
          "success_rate": "50-70% within 24 hours",
          "advantages": "Safe in structural heart disease, hemodynamically stable",
          "onset": "4-24 hours"
        },
        "ibutilide": {
          "dosing": "1mg IV over 10min, may repeat once after 10min",
          "success_rate": "70-80% within 90 minutes",
          "monitoring": "Continuous telemetry for ≥4 hours (QT prolongation)",
          "contraindications": "QTc >440ms, hypokalemia, CHF"
        },
        "propafenone": {
          "dosing": "1.5-2mg/kg IV over 10-20min",
          "success_rate": "60-80% within 2 hours",
          "contraindications": "Structural heart disease, CAD, heart failure"
        }
      }
    },
    "contraindications": [
      "Intracardiac thrombus",
      "Active infection/sepsis",
      "Severe electrolyte abnormalities",
      "Digoxin toxicity",
      "Recent myocardial infarction (relative)"
    ],
    "complications": [
      "Thromboembolism (0.5-3%)",
      "Arrhythmias (VT/VF rare with synchronization)",
      "Bradycardia/asystole (usually transient)",
      "Hypotension",
      "Skin burns (rare with biphasic)"
    ]
  }
}
